NCT00280956 - Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease | Biotech Hunter

Enrollment

2,000

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions

Crohn's Disease

Interventions

DRUG

natalizumab

Trial Locations (1)

92121

Performed only at CD251, CD301, CD303, CD306, and CD307 sites globally. No general public enrollment. The study is managed from the office of Elan Pharmaceuticals, Inc. in, San Diego